Does prednisone cause gynaecomastia? This is a question that patients and clinicians occasionally raise, particularly during long-term corticosteroid therapy. Prednisone — or its active form prednisolone, which is the standard oral corticosteroid in UK clinical practice — is prescribed for a wide range of conditions, from rheumatoid arthritis to inflammatory bowel disease. Whilst direct evidence linking prednisolone to true gynaecomastia is limited, indirect hormonal effects and corticosteroid-related weight gain may play a role in some individuals. This article explores the evidence, the hormonal mechanisms involved, and when to seek medical advice.

Can Prednisone Cause Gynaecomastia?

Direct evidence linking prednisone or prednisolone to true gynaecomastia is limited, and neither carries a specific MHRA or EMA warning; however, indirect hormonal effects and weight gain may contribute in some individuals.

Not sure if this is normal? Chat with one of our pharmacists →

Prednisone is a synthetic corticosteroid that is occasionally prescribed in the UK; however, it is worth noting that prednisolone — the active form to which prednisone is converted in the liver — is the standard oral corticosteroid used in UK clinical practice. Both medicines are used for conditions ranging from inflammatory bowel disease and rheumatoid arthritis to asthma and certain cancers. One question that patients and clinicians occasionally raise is whether prednisone (or prednisolone) can cause gynaecomastia — the benign enlargement of glandular breast tissue in males.

It is important to distinguish true gynaecomastia (proliferation of glandular breast tissue) from pseudogynaecomastia (lipomastia), which is an increase in fatty tissue beneath the nipple without glandular enlargement. This distinction matters because corticosteroids can cause weight gain and increased adiposity, which may produce the appearance of breast enlargement without true glandular change.

The direct evidence linking prednisone or prednisolone specifically to true gynaecomastia is limited. Corticosteroids do not appear prominently in established UK evidence-graded lists of medicines most commonly associated with gynaecomastia (such as those published by the Specialist Pharmacy Service), and there is no specific regulatory warning from the MHRA or EMA identifying prednisone or prednisolone as a confirmed cause. However, this does not entirely rule out a possible association, particularly in certain clinical contexts.

The underlying conditions for which corticosteroids are prescribed — such as liver disease, hyperthyroidism, or certain cancers — may themselves be independent risk factors for gynaecomastia. Distinguishing drug-related effects from disease-related changes can therefore be clinically challenging.

Patients who notice breast swelling, tenderness, or enlargement whilst taking prednisone or prednisolone should not assume it is necessarily caused by the medication, but they should report it to their GP or prescribing clinician promptly for proper assessment.

How Corticosteroids Affect Hormone Balance

Prolonged corticosteroid use can suppress LH and FSH, reducing testosterone synthesis, and promotes weight gain that increases peripheral aromatisation of androgens to oestrogens — both mechanisms that may favour gynaecomastia.

To understand the potential link between corticosteroids and gynaecomastia, it is helpful to consider how these medicines interact with the body's hormonal systems. Prednisone is a prodrug converted in the liver to its active form, prednisolone, which binds to glucocorticoid receptors and exerts widespread anti-inflammatory and immunosuppressive effects.

One key mechanism relevant to gynaecomastia is the effect of corticosteroids on the hypothalamic-pituitary-gonadal (HPG) axis. Prolonged corticosteroid use can suppress the production of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces testosterone synthesis in the testes. A relative reduction in testosterone — or an imbalance between oestrogen and androgen activity — is the central hormonal driver of gynaecomastia.

It is also important to note that exogenous corticosteroids suppress adrenocorticotrophic hormone (ACTH) secretion, which in turn reduces adrenal androgen production rather than increasing it. This suppression of adrenal androgens may contribute to a relative shift in the oestrogen-to-androgen ratio in some individuals.

Additionally, corticosteroids may:

• Promote weight gain and increased adiposity, which increases peripheral conversion (aromatisation) of androgens to oestrogens in fatty tissue

• Affect sex hormone-binding globulin (SHBG) levels, potentially altering the ratio of free testosterone to oestrogen, though the clinical significance of this effect with prednisolone specifically is not well established

These indirect hormonal effects, particularly with long-term use, may create conditions that are more conducive to breast tissue changes in some individuals. It is important to emphasise that these mechanisms are plausible and theoretical rather than definitively proven in the context of corticosteroid-induced gynaecomastia, and individual susceptibility varies considerably. As noted above, weight-related pseudogynaecomastia should also be considered.

Other Medicines and Factors Linked to Gynaecomastia

Spironolactone, anti-androgens, 5-alpha-reductase inhibitors, and anabolic steroids carry far stronger evidence of causing gynaecomastia than corticosteroids; underlying conditions such as liver cirrhosis and hypogonadism are also recognised causes.

When evaluating gynaecomastia in a patient taking prednisone or prednisolone, it is essential to consider the broader clinical picture, as many other medicines and conditions are far more strongly associated with this condition. The following is informed by UK resources including the Specialist Pharmacy Service (SPS) and the British National Formulary (BNF).

Medicines with well-established links to gynaecomastia include:

• Spironolactone — an aldosterone antagonist that blocks androgen receptors; one of the most commonly implicated medicines

• Anti-androgens (e.g., bicalutamide, cyproterone acetate, enzalutamide) — used in prostate cancer treatment

• 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) — used for benign prostatic hyperplasia and male-pattern hair loss

• Anabolic steroids and exogenous testosterone — paradoxically, exogenous androgens can be aromatised to oestrogens

• Digoxin — a cardiac glycoside with oestrogenic properties

• Cimetidine — a histamine H2 receptor antagonist

• Prolactin-elevating antipsychotics (e.g., risperidone, haloperidol) — raised prolactin can contribute to breast tissue changes; the evidence for antidepressants is less consistent

• Antiretrovirals (e.g., efavirenz) — associated with gynaecomastia in some studies

• Proton pump inhibitors — occasionally cited, but the evidence is weak and inconsistent; this association should not be overstated

Physiological and pathological conditions that are recognised causes include:

• Puberty — transient gynaecomastia is common in adolescent males

• Hypogonadism — primary or secondary testosterone deficiency

• Liver cirrhosis — impairs oestrogen metabolism

• Hyperthyroidism — increases sex hormone-binding globulin

• Chronic kidney disease — associated with hormonal disruption

• Obesity — promotes peripheral aromatisation

• Klinefelter syndrome — a recognised predisposing condition

• Testicular or adrenal tumours — rare but important to exclude

A thorough medication review and clinical history are therefore essential before attributing gynaecomastia to prednisone or prednisolone. In many cases, a combination of factors — including the underlying disease, concurrent medications, and lifestyle factors — may collectively contribute to the presentation.

When to Speak to a GP or Specialist

Males should contact their GP promptly if they notice unilateral breast swelling, a hard lump, nipple discharge, or rapid breast enlargement, as these features require assessment to exclude serious causes including male breast cancer.

Any male patient who notices breast swelling, tenderness, a palpable lump beneath the nipple, or nipple discharge whilst taking prednisone, prednisolone, or any other medication should seek a medical review. Whilst gynaecomastia is usually benign, it is important to exclude other causes, including rare but serious conditions such as male breast cancer.

You should contact your GP promptly if you experience:

• Unilateral (one-sided) breast swelling or a hard, irregular lump

• Nipple discharge, particularly if bloodstained

• Rapid or progressive breast enlargement

• Breast changes accompanied by testicular pain or swelling

• Significant pain or discomfort in the breast area

Your GP will typically take a detailed history, including a full medication review, and perform a physical examination. Depending on findings, they may arrange blood tests to assess hormone levels — including testosterone, oestradiol, LH, FSH, prolactin, and thyroid function — as well as liver and renal function tests. Serum human chorionic gonadotrophin (hCG) and alpha-fetoprotein (AFP) may also be measured if a testicular or germ cell tumour is suspected. Breast imaging or testicular ultrasound may be arranged where clinically indicated.

In line with NICE guidance on suspected cancer (NG12), your GP should refer you urgently via the two-week-wait pathway if you are aged 30 or over with an unexplained breast lump, or aged 50 or over with unilateral nipple changes (such as discharge, retraction, or skin changes). For males under 30 with an unexplained breast lump, a non-urgent referral to a specialist may be appropriate. For confirmed benign gynaecomastia, management will depend on the underlying cause, severity, and duration of symptoms.

Patients should not stop taking prednisone or prednisolone without first consulting their prescribing clinician, as abrupt withdrawal can cause serious adverse effects, including adrenal insufficiency.

Managing Gynaecomastia During Corticosteroid Treatment

Management is individualised and may include dose reduction, steroid-sparing agents, weight management, and monitoring; tamoxifen under specialist supervision may be considered for persistent cases within the first 6–12 months.

If gynaecomastia is identified in a patient receiving prednisone or prednisolone, management should be individualised and guided by the clinical context. The first step is always to determine whether the corticosteroid is genuinely contributing to the breast changes, or whether another cause — including pseudogynaecomastia related to weight gain — is more likely.

Where the corticosteroid is considered a contributing factor, the prescribing clinician will weigh the benefits of continued treatment against the impact of gynaecomastia on the patient's quality of life. In many cases, the underlying condition being treated will take clinical priority, and the dose may be gradually tapered to the lowest effective level rather than discontinued entirely. Shared decision-making between the patient and their clinical team is central to this process.

Practical management strategies may include:

• Dose reduction — using the minimum effective dose to limit hormonal disruption

• Steroid-sparing agents — introducing alternative immunosuppressants (e.g., methotrexate, azathioprine) to allow corticosteroid reduction where appropriate

• Lifestyle measures — weight management to reduce peripheral aromatisation of androgens and to address pseudogynaecomastia

• Monitoring — regular review of breast symptoms and hormone levels where clinically indicated

• Psychological support — gynaecomastia can cause significant distress; referral for counselling may be appropriate

In persistent or severe cases that do not resolve after addressing the underlying cause, pharmacological options such as tamoxifen (an oestrogen receptor modulator, used off-label) have been used under specialist supervision with some evidence of benefit. Pharmacological treatment is most likely to be effective within the first 6–12 months, when breast tissue is still in the proliferative (active) phase; established fibrotic gynaecomastia is less likely to respond. Aromatase inhibitors are generally not considered first-line for gynaecomastia due to limited evidence of efficacy. Surgical correction (reduction mammoplasty) remains an option for longstanding, symptomatic gynaecomastia that has not responded to other measures. Any pharmacological or surgical intervention would typically be initiated or overseen by a specialist.

Reporting Suspected Side Effects: MHRA Yellow Card Scheme

Patients and clinicians can report suspected corticosteroid side effects, including breast changes, via the MHRA Yellow Card scheme online, by app, or through a healthcare professional.

Experiencing these side effects? Our pharmacists can help you navigate them →

In the UK, patients and healthcare professionals are encouraged to report suspected side effects of medicines — including prednisone and prednisolone — through the MHRA Yellow Card scheme. This pharmacovigilance system, run by the Medicines and Healthcare products Regulatory Agency (MHRA), allows ongoing monitoring of medicine safety in real-world use and helps identify potential signals that may not have been apparent during clinical trials.

Reporting a suspected side effect does not confirm that the medicine caused it, but it contributes valuable data to ongoing safety monitoring. Yellow Card reports can be submitted:

• Online at the MHRA Yellow Card website (yellowcard.mhra.gov.uk)

• Via the Yellow Card app, available on iOS and Android

• Through a GP, pharmacist, or nurse, who can submit a report on a patient's behalf

Patients taking prednisone or prednisolone on a long-term basis should also be aware of the broader side effect profile of corticosteroids, which includes osteoporosis, adrenal suppression, increased infection risk, weight gain, and mood changes. Regular monitoring and review appointments with their GP or specialist are an important part of safe long-term corticosteroid management, in line with NICE recommendations.

If you are concerned about any new or unexpected symptom whilst taking a corticosteroid — including changes to breast tissue — the most important step is to speak to your GP or pharmacist rather than stopping the medication abruptly. Open communication with your healthcare team ensures that any potential side effects are properly assessed and managed in the context of your overall treatment plan.

Frequently Asked Questions